Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHYF) Other Non-Current Assets (2017 - 2025)

Historic Other Non-Current Assets for Innate Pharma (IPHYF) over the last 9 years, with Q2 2025 value amounting to $653140.7.

  • Innate Pharma's Other Non-Current Assets rose 61353.85% to $653140.7 in Q2 2025 from the same period last year, while for Jun 2025 it was $653140.7, marking a year-over-year increase of 61353.85%. This contributed to the annual value of $614442.3 for FY2024, which is 55640.8% up from last year.
  • According to the latest figures from Q2 2025, Innate Pharma's Other Non-Current Assets is $653140.7, which was up 61353.85% from $614442.3 recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Other Non-Current Assets ranged from a high of $653140.7 in Q2 2025 and a low of $91535.5 during Q2 2024
  • Over the past 5 years, Innate Pharma's median Other Non-Current Assets value was $158991.4 (recorded in 2022), while the average stood at $253287.3.
  • Per our database at Business Quant, Innate Pharma's Other Non-Current Assets plummeted by 9982.06% in 2021 and then surged by 61353.85% in 2025.
  • Over the past 5 years, Innate Pharma's Other Non-Current Assets (Quarter) stood at $169307.7 in 2021, then dropped by 10.21% to $152016.8 in 2022, then plummeted by 38.42% to $93606.8 in 2023, then soared by 556.41% to $614442.3 in 2024, then grew by 6.3% to $653140.7 in 2025.
  • Its last three reported values are $653140.7 in Q2 2025, $614442.3 for Q4 2024, and $91535.5 during Q2 2024.